XML 11 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2017
Dec. 31, 2016
Current Assets    
Cash $ 381,056 $ 182,561
Trade accounts receivable, net 555,708 444,743
Other receivables 2,250
Inventory, net 136,938 160,270
Total Current Assets 1,073,702 789,824
Current Liabilities    
Accounts payable and accrued expenses 562,220 752,930
Derivative liabilities 1,809,890 192,254
Convertible notes payable 100,000
Notes payable, net of discount 25,000 106,365
Total Current Liabilities 2,397,110 1,151,549
Immudyne, Inc. Stockholders' Equity (Deficit)    
Common stock, $0.01 par value; 50,000,000 shares authorized, 40,543,373 and 35,570,157 shares issued, 40,205,573 and 35,245,157 outstanding as of March 31, 2017 and December 31, 2016, respectively 405,433 355,701
Additional paid-in capital 9,363,160 9,070,064
Accumulated (deficit) (10,738,687) (9,693,882)
Equity (970,094) (268,117)
Treasury stock, 337,800 and 325,000 shares, at cost (90,204) (87,053)
Total Immudyne, Inc. Stockholders' (Deficit) (1,060,298) (355,170)
Non-controlling interest (263,110) (6,555)
Total Stockholders' (Deficit) (1,323,408) (361,725)
Total Liabilities and Stockholders' (Deficit) $ 1,073,702 $ 789,824